IBXXF (Imagion Biosystems) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is Imagion Biosystems Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Imagion Biosystems's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

IBXXF vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, Imagion Biosystems's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's Margin of Safety % (DCF Earnings Based) falls into.


Imagion Biosystems Business Description

Other Exchanges IBX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.